Sign in

    Ramy Farid, Ph.D.

    President and Chief Executive Officer at Schrodinger Inc
    Board
    Since January 2017
    Age
    59 years
    Education
    Holds a B.S. in Chemistry from the University of Rochester, a Ph.D. in Chemistry from the California Institute of Technology, and completed a National Institutes of Health postdoctoral fellowship in the Department of Biochemistry and Biophysics at the University of Pennsylvania.
    Tenure
    Joined in 2002 as a product manager and held positions including Vice President, Senior Vice President, President since January 2008, and Chief Executive Officer since January 2017.

    Also at Schrodinger Inc

    GPM
    Geoffrey Porges, MBBS
    Executive Vice President and Chief Financial Officer
    MDM
    Margaret Dugan, M.D.
    Chief Medical Officer
    PL
    Patrick Lorton
    Chief Operating Officer, Software

    About

    Dr. Farid has built a distinguished career bridging scientific expertise with strategic leadership in the biotechnology field. His early academic accomplishments and postdoctoral experience paved the way for an impactful career that began in academia and evolved in industry, demonstrating his commitment to advancing science and innovation.

    Since his entry into the company in 2002, he quickly advanced through various key roles, contributing significantly to the company’s growth. His progression from product manager to vice president, and later senior vice president, set the stage for his pivotal appointments as President and, subsequently, Chief Executive Officer, underscoring his enduring influence on the company's strategic direction.

    Beyond his executive responsibilities, Dr. Farid also lends his expertise to several board roles, enhancing the company’s involvement and impact in the broader biotechnology arena. His participation in multiple biotech initiatives reflects his ability to translate scientific innovation into successful business ventures, fostering industry advancements and collaborative partnerships.

    $SDGR Performance Under Ramy Farid, Ph.D.

    Past Roles

    Organization Role Date Range Details
    Schrödinger, Inc. Senior Vice President January 2005 to December 2007 Held before becoming President and CEO
    Schrödinger, Inc. Vice President, Scientific Development and Product Management January 2003 to December 2004 Held before becoming President and CEO
    Schrödinger, Inc. Product Manager January 2002 to December 2002 Held before becoming President and CEO
    Rutgers University Assistant Professor, Chemistry Department N/A Position held prior to joining Schrödinger, Inc.
    University of Pennsylvania NIH Postdoctoral Fellow, Department of Biochemistry and Biophysics N/A Position held prior to joining Schrödinger, Inc.

    External Roles

    Organization Role Date Range Details
    Structure Therapeutics, Inc. Board of Directors Current Publicly traded biopharmaceutical company

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$704,080 Annual4% increase over 2023
    Target Cash Incentive Award65% of Base Salary Annual payout in early 2025 5% increase over 2023; based on performance metrics similar to 2023

    Performance Compensation

    Data from  FY 2024

    Target Cash Incentive Award

    MetricValueAdditional Details
    Award Percentage65% of Base Salary Payout based on fiscal 2024 performance
    Increase Over 20235% increase Reflects enhanced performance expectations

    Stock Options

    MetricValueAdditional Details
    Grant DateMarch 4, 2024
    Exercise Price$25.24 Based on closing price on grant date
    Premium-Priced Option87,271 shares at $27.76 110% of closing price on grant date
    Vesting Schedule25% at first anniversary, then 2.0833% monthly Time-based vesting

    Performance-Based Restricted Stock Units (PRSUs)

    MetricValueAdditional Details
    Target PRSUs35,000 shares Target level at full achievement
    Threshold PRSUs17,500 shares (50% of target) Minimum performance requirement
    Maximum PRSUs52,500 shares (150% of target) Exceptional performance cap
    Grant DateMarch 4, 2024
    Grant Date Stock Price$25.24 Closing price on grant date
    Grant Date Fair Value$0 Conditions not probable for performance at grant date
    Vesting ScheduleVests after filing of FY-end 10-K (Dec 31, 2026) Vesting contingent on achieving performance metrics
    Evaluation PeriodThrough December 31, 2025 Performance metrics: software performance, Schr\u00f6dinger therapeutics group, and operating performance